Meet Us at ASCO 2026
ClearNote Health will be at ASCO 2026 presenting landmark new clinical data from our multi-cohort validation study for pancreatic cancer early detection using liquid biopsy.
Connect with our team to explore the latest from Virtuoso™, our epigenomic liquid biopsy platform, and Avantect®, our multiomics early detection test. We’d love to find time to connect.
Discover more: https://go.clearnotehealth.com/ASCO-2026